Investing.com UK - Financial Markets Worldwide
Get 40% Off
Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

FDA Slaps Partial Hold On DBV Technologies' Pivotal Trial Of Peanut Allergy Patch

Published 22/09/2022, 11:31
Updated 22/09/2022, 12:10
© Reuters. FDA Slaps Partial Hold On DBV Technologies' Pivotal Trial Of Peanut Allergy Patch

  • The FDA has instituted a partial clinical hold on DBV Technologies SA's (NASDAQ: DBVT) VITESSE Phase 3 study to assess the efficacy and safety of epicutaneous immunotherapy with the modified Viaskin Peanut 250 µg patch in peanut-allergic children ages 4 to 7.
  • In the partial clinical hold letter, the FDA specifies changes to elements of the VITESSE protocol with the intent for the trial to support a future marketing application submission.
  • Within the FDA's communication, the modifications address design elements, including the statistical analysis of adhesion, minimum daily wear time, and technical alignments in methods of categorizing data to meet study objectives and the total number of trial participants on active treatment.
  • DBV has not yet begun screening or recruiting subjects in the VITESSE study.
  • The partial clinical hold is specific to VITESSE and does not impact any other ongoing DBV clinical studies.
  • DBV started the trial earlier this month and expected to enroll 600 subjects. The first patient screened is expected in Q4 2022, with the last patient screened by year-end 2023.
  • In June, the company announced positive results from the pivotal Phase 3 EPITOPE trial of Viaskin Peanut 250 µg for peanut-allergic toddlers ages 1 to 3 years.
  • Price Action: DBVT shares closed 14% lower at $1.90 during after-hours trading on Wednesday.

Read the original article on Benzinga

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.